论文部分内容阅读
为了更好地评价非霍奇金淋巴瘤(NHL)的临床疗效和预后,通过复习国内外相关文献,发现多种指标可以有效地运用于临床,包括传统评价国际预后指数、病理类型、临床分期、治疗方法、初治疗效、病灶稳定或病灶进展、最大肿瘤直径、结外受累部位数、乳酸脱氢酶等以及新近评价肿瘤标志物CA125、分子生物学指标、免疫及相关指标、正电子射出断层造影CT中2-氟-2-脱氧-D-葡萄糖最大标化摄取值等。该文就NHL病临床疗效与预后评价的相关指标予以综述。
In order to evaluate the clinical efficacy and prognosis of non-Hodgkin’s lymphoma (NHL) better, we found that many indicators can be effectively used in clinic, including the traditional evaluation of international prognostic index, pathological type, clinical stage , Treatment, initial treatment effect, stable or lesion progression, maximum tumor diameter, extranodal involvement sites, lactate dehydrogenase, etc., as well as the recent evaluation of tumor marker CA125, molecular biological indicators, immune and related indicators, positron emission 2-fluoro-2-deoxy-D-glucose maximum standardization in CT and so on. This article reviews the clinical efficacy and prognostic indicators of NHL.